Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New imaging showdown: can MBI outperform DBT for dense breast cancer detection?

NCT ID NCT03220893

First seen Feb 03, 2026 · Last updated May 25, 2026 · Updated 21 times

Summary

This study compared two breast cancer screening methods—molecular breast imaging (MBI) and digital breast tomosynthesis (DBT)—in over 3,000 women aged 40-75 with dense breast tissue. MBI uses a small amount of radioactive material to spot active cancer cells, while DBT is a type of 3D mammogram. The goal was to see if adding MBI to standard DBT screening finds more invasive cancers early, when treatment is easier.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Henry Ford Hospital

    Detroit, Michigan, 48202, United States

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Mayo Clinic Health System-Franciscan Healthcare

    La Crosse, Wisconsin, 54601, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

  • Toledo Clinic Cancer Centers-Toledo

    Toledo, Ohio, 43623, United States

Conditions

Explore the condition pages connected to this study.